Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 250

1.

Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosis.

Lane DA, Lowe GD, Flynn A, Thompson E, Ireland H, Erdjument H.

Br J Haematol. 1987 Aug;66(4):523-7.

PMID:
3663509
2.

Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.

Lane DA, Flynn A, Ireland H, Erdjument H, Samson D, Howarth D, Thompson E.

Br J Haematol. 1987 Apr;65(4):451-6.

PMID:
3580302
3.

An abnormal antithrombin III (AT III) with low heparin affinity: AT III Clichy.

Aiach M, François D, Priollet P, Capron L, Roncato M, Alhenc-Gelas M, Fiessinger JN.

Br J Haematol. 1987 Aug;66(4):515-22.

PMID:
3663508
4.

Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.

Jørgensen M, Petersen LC, Thorsen S.

J Lab Clin Med. 1984 Aug;104(2):245-56.

PMID:
6747440
5.

Antithrombin III Kumamoto II; a single mutation at Arg393-His increased the affinity of antithrombin III for heparin.

Okajima K, Abe H, Wagatsuma M, Okabe H, Takatsuki K.

Am J Hematol. 1995 Jan;48(1):12-8.

PMID:
7832187
6.

Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.

Okajima K, Ueyama H, Hashimoto Y, Sasaki Y, Matsumoto K, Okabe H, Inoue M, Araki S, Takatsuki K.

Thromb Haemost. 1989 Feb 28;61(1):20-4.

PMID:
2749590
7.

Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.

Collen D, Schetz J, de Cock F, Holmer E, Verstraete M.

Eur J Clin Invest. 1977 Feb;7(1):27-35.

PMID:
65284
8.

A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville.

Aiach M, Nora M, Fiessinger JN, Roncato M, François D, Gelas MA.

Thromb Res. 1985 Sep 1;39(5):559-70.

PMID:
4082101
9.

Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin.

Ireland H, Lane DA, Thompson E, Walker ID, Blench I, Morris HR, Freyssinet JM, Grunebaum L, Olds R, Thein SL.

Br J Haematol. 1991 Sep;79(1):70-4.

PMID:
1911389
10.
11.
12.

Antithrombin Sheffield: amino acid substitution at the reactive site (Arg393 to His) causing thrombosis.

Lane DA, Erdjument H, Flynn A, Di Marzo V, Panico M, Morris HR, Greaves M, Dolan G, Preston FE.

Br J Haematol. 1989 Jan;71(1):91-6.

PMID:
2917133
13.
14.

Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis.

Raja SM, Chhablani N, Swanson R, Thompson E, Laffan M, Lane DA, Olson ST.

J Biol Chem. 2003 Apr 18;278(16):13688-95. Epub 2003 Feb 18.

15.

Antithrombin III Nagasaki (Ser116-Pro): a heterozygous variant with defective heparin binding associated with thrombosis.

Okajima K, Abe H, Maeda S, Motomura M, Tsujihata M, Nagataki S, Okabe H, Takatsuki K.

Blood. 1993 Mar 1;81(5):1300-5.

16.
17.

Antithrombin III Geneva: a hereditary abnormal AT III with defective heparin cofactor activity.

de Moerloose PA, Reber G, Vernet P, Minazio P, Bouvier CA.

Thromb Haemost. 1987 Apr 7;57(2):154-7.

PMID:
3603409
18.
19.

Homozygous variant of antithrombin III: AT III Fontainebleau.

Boyer C, Wolf M, Vedrenne J, Meyer D, Larrieu MJ.

Thromb Haemost. 1986 Aug 20;56(1):18-22.

PMID:
3775688
20.

Antithrombin III "Northwick Park": a variant antithrombin with normal affinity for heparin but reduced heparin cofactor activity.

Howarth DJ, Samson D, Stirling Y, Seghatchian MJ.

Thromb Haemost. 1985 Jun 24;53(3):314-9.

PMID:
4049307

Supplemental Content

Support Center